Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001224:Aspartic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity; D003570:Cytidine Triphosphate / Q000378:metabolism; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D010292:Paresthesia / Q000139:chemically induced; D010746:Phosphonoacetic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000633:toxicity; D012871:Skin Diseases / Q000139:chemically induced; D014544:Uridine Triphosphate / Q000378:metabolism
D000970:Antineoplastic Agents; D009943:Organophosphorus Compounds; D001224:Aspartic Acid; D003570:Cytidine Triphosphate; C013195:sparfosic acid; D010746:Phosphonoacetic Acid; D014544:Uridine Triphosphate